Recruiting

A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(9 sites)

United States

Yale University, New Haven, Connecticut

Mount Sinai Cancer Research Program, Miami Beach, Florida

Orlando Health Cancer Institute, Orlando, Florida

Rutgers Cancer Institute, New Brunswick, New Jersey

NYU Langone Health, New York, New York

UPenn Lancaster-Ann B. Barshinger Cancer Institute, Lancaster, Pennsylvania

Vanderbilt University Medical Center, Nashville, Tennessee

Mays Cancer Center at University of Texas Health at San Antonio, San Antonio, Texas

Inova Schar Cancer, Fairfax, Virginia